Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review.
Kaili YangJiarui LiZhao SunLin ZhaoChun-Mei BaiPublished in: Therapeutic advances in medical oncology (2020)
Retreatment with ICIs is feasible for cancer patients considering its encouraging efficacy and tolerable safety. Further prospective trials are needed to explore more promising strategies and identify suitable populations for retreatment.
Keyphrases